Key Points {#FPar1}
==========

In pediatric patients with major depressive disorder, there was no significant difference between vilazodone and placebo in primary or secondary efficacy parameters.The safety profile of vilazodone in pediatric patients with major depressive disorder was similar to that observed in the adult population.

Introduction {#Sec1}
============

Major depressive disorder (MDD) is a common mental health problem in adolescents. For individuals between the ages of 13 and 17 years, lifetime prevalence in the United States is estimated at 12.6% for a major depressive episode (single or recurrent lifetime) and 10.6% for MDD \[[@CR1]\]. Approximately 40% of pediatric patients recover without specific treatment during the first depressive episode; however, patients who recover remain at risk for recurrence or dysthymia, while those who do not recover have an increased risk for chronic depression \[[@CR2]\]. The presence of depressive symptoms during early adolescence is associated with later depression, anxiety disorders, substance abuse, suicide risk, school failure, recurrent unemployment, and early pregnancy \[[@CR3]\]. If left untreated, adolescent depression can affect the development of emotional, cognitive, and social skills; interfere with family relationships; and lead to substantial morbidity and mortality \[[@CR4]\].

Evidence-based treatments, which include psychosocial interventions and pharmacotherapy, can improve outcomes in childhood and adolescent depressive disorders. Acute and continuation treatment of depression is recommended for all adolescent patients, with the goal of achieving significant reduction in symptoms and consolidating treatment response to prevent relapse; maintenance treatment may be recommended for patients with severe or chronic depressive conditions to deter recurrence \[[@CR4]\]. Supportive treatment approaches (e.g., active listening, problem solving, coping skills) may be sufficient for adolescents with uncomplicated or brief depression; for adolescents who do not respond or who have complicated or severe depression, psychotherapy, such as cognitive behavioral therapy (CBT) or interpersonal psychotherapy (IPT), pharmacotherapy, or a combination of approaches is warranted \[[@CR4]\].

Despite the recommendations above, the most effective approach to depression treatment in pediatric patients is uncertain. CBT and IPT are the most widely studied nonpharmacological approaches to depression treatment in adolescents \[[@CR5]\]. While both treatments, alone and in combination with antidepressant medication, have demonstrated efficacy in adolescents, findings have been inconsistent \[[@CR4]\]. Additionally, several antidepressants have been evaluated for depression treatment in children and adolescents, but only the selective serotonin reuptake inhibitors (SSRIs) fluoxetine (ages 8--18 years) and escitalopram (ages 12--17 years) are approved by the US Food and Drug Administration (FDA) for the treatment of MDD in pediatric patients \[[@CR6]--[@CR8]\]. Given the prevalence of depressive episodes in adolescents and the lack of approved pharmacotherapies, there is an ongoing need for effective treatment in this population \[[@CR9]\].

Vilazodone is an SSRI and 5-HT~1A~ receptor partial agonist that is approved by the FDA for the treatment of MDD in adults \[[@CR10]\]. The efficacy and safety of vilazodone in adults was evaluated in four randomized, double-blind, placebo-controlled, 8- to 10-week clinical trials \[[@CR11]--[@CR14]\] and one long-term, 52-week, open-label study \[[@CR15]\]. We are presenting results from a phase 3 study conducted to evaluate the efficacy, safety, and tolerability of vilazodone in adolescent outpatients with MDD.

Methods {#Sec2}
=======

The study was conducted in the United States from 2013 to 2016 at 56 study centers in full compliance with the Declaration of Helsinki and International Conference on Harmonisation guidelines for Good Clinical Practice. Each study center was experienced in treating the pediatric population and used available guidelines to minimize patient risk or distress. The investigator at each study center was responsible for study management and ensuring study compliance. The protocol and amendments were approved by an institutional review board at each study center, and all patients (or a parent or legal guardian) provided written informed consent.

Study Design and Patient Selection {#Sec3}
----------------------------------

This was a 10-week, double-blind, randomized, placebo-controlled, parallel-group, fixed-dose study of vilazodone 15 mg/day or 30 mg/day in adolescent patients with MDD (NCT01878292). The study comprised a 1-week screening period, followed by an 8-week double-blind treatment period, and a 1-week double-blind down-taper period.

Male and female patients aged 12--17 years with a diagnosis of MDD for a minimum of 6 weeks were included in the study; diagnosis was based on *Diagnostic and Statistical Manual of Mental Disorders,* Fourth Edition, Text Revision (DSM-IV-TR) \[[@CR16]\] criteria. To ensure an accurate MDD diagnosis, the Kiddie Schedule for Affective Disorders and Schizophrenia--Present and Lifetime (K-SADS-PL) interview \[[@CR17]\], administered by a trained clinician to interview pediatric patients and caregivers, was used to confirm MDD diagnosis. Clinical inclusion criteria required a Children's Depression Rating Scale--Revised (CDRS-R) \[[@CR18]\] total score ≥ 40 and a Clinical Global Impressions--Severity (CGI-S) \[[@CR19]\] score ≥ 4. Patients were required to have a caregiver who was responsible for safety monitoring and could provide information about the patient's condition, oversee administration of study drug, and accompany the patient to all study visits. Psychotherapy or behavior therapy were allowed if either was initiated at least 3 months prior to screening and there was no plan to change such therapies during the study.

Key exclusion criteria included a principal DSM-IV-TR Axis I diagnosis other than MDD in the past 3 months or prior diagnosis of mental retardation or other cognitive disorders; comorbid diagnoses of learning disorders, attention deficit disorder with or without hyperactivity, communication disorders, separation anxiety disorder, dysthymic disorder, oppositional defiant disorder, and anxiety disorders were allowed. Patients with nonresponse to adequate treatment (i.e., at least 8 weeks' duration) with two or more SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs) or the need for concomitant psychotropic medication were excluded. History of drug or alcohol abuse or dependence within the past year was also exclusionary. Patients were additionally excluded for significant suicide risk judged by the investigator based on the psychiatric interview or information collected from the Columbia-Suicide Severity Rating Scale (C-SSRS) \[[@CR20]\], or suicide attempt within the past year. Any unstable medical condition or any condition that could interfere with study conduct, confound interpretation of study results, or endanger patient well-being was an additional reason for exclusion.

Randomization, Blinding, and Treatment {#Sec4}
--------------------------------------

Computerized randomization codes were generated; blinding of patients, investigators, and study site personnel was implemented and maintained by interactive voice/web response systems. Breaking the blind for any reason resulted in discontinuation from the study. Based on modeling and simulation of adult pharmacokinetic (PK) data from vilazodone studies (a dose range of 2.5--80 mg/day) considering the vilazodone tablet strengths available (5 mg, 10 mg, and 20 mg), dosing schemes of 15 mg/day and 30 mg/day were selected for this study. Each approach was expected to lead to similar up-titration and steady-state exposures as those observed with 20 mg and 40 mg, respectively, in adult patients. Study medication was dispensed as vilazodone 5-, 10-, and 20-mg tablets and matching placebo tablets, identical in appearance and packaging. Eligible patients were randomized (1:1:1) to placebo or fixed-dose vilazodone 15 mg/day or 30 mg/day. Patients randomized to vilazodone received 5 mg/day for days 1--3 and 10 mg/day for days 4--7. Patients in the vilazodone 15-mg/day group were titrated up to 15 mg/day starting at week 2; patients in the vilazodone 30-mg/day group were titrated up to 20 mg/day starting at week 2 and to 30 mg/day starting at week 3. During the 1-week double-blind down-taper period, patients receiving vilazodone 15 mg/day were titrated down to 5 mg/day for 7 days; patients receiving vilazodone 30 mg/day were titrated down to 15 mg/day for 4 days, then 5 mg/day for 3 days (see the electronic supplementary material, Supplemental Figure 1). Patients randomized to placebo continued taking placebo tablets during the 7-day down-taper period.

Efficacy and Safety Parameters {#Sec5}
------------------------------

The prespecified primary efficacy parameter was change from baseline to week 8 in CDRS-R total score \[assessed at screening (week −1), baseline (week 0), and the end of double-blind study weeks 1, 2, 3, 4, 6, and 8\]. The prespecified secondary efficacy parameter was change from baseline to week 8 in CGI-S score, assessed at the same study weeks as the primary efficacy parameter. Additional prespecified efficacy parameters were assessed at each post-baseline visit (weeks 1, 2, 3, 4, 6, and 8): CGI--Improvement (CGI-I) \[[@CR19]\] score, CDRS-R response (≥ 40% reduction from baseline in CDRS-R total score), and CDRS-R remission (total score ≤ 28). A post hoc analysis was conducted to determine CGI-I response \[score of 1 (very much improved) or 2 (much improved)\]. Safety was assessed by adverse event (AE) reports, clinical laboratory tests, vital sign measurement, physical examinations, electrocardiogram (ECG) findings, and C-SSRS assessments. PK samples were collected at weeks 3, 6, and 8 (visits 5, 7, and 8).

Determination of Sample Size {#Sec6}
----------------------------

Based on a mixed-effect model for repeated measures (MMRM) adjusted for multiple comparisons using the matched parallel gatekeeping procedure, a sample size of 495 patients (165 per treatment group) was planned to provide 85% power to detect an effect size of 0.36 at a two-sided significance level of 0.5%. The simulation assumed a correlation of 0.7 between the repeated measures, and a dropout rate of 17%, based on historical studies in pediatric patients with MDD. Based on a prespecified interim analysis of blinded sample size re-estimation, the sample size was later increased from 495 to 525 patients (175 per group) to maintain the desired 85% power.

Statistical Methods {#Sec7}
-------------------

Safety analyses were conducted in the safety population, defined as all patients in the randomized population who took at least one dose of double-blind study drug. Efficacy analyses were based on the intent-to-treat (ITT) population (all patients in the safety population who had a baseline and one or more post-baseline CDRS-R total score assessment).

The primary efficacy analysis, change from baseline to week 8 in CDRS-R total score, was performed using MMRM with treatment group, study center, visit, and treatment group-by-visit interaction as the fixed effects and the baseline value and baseline value-by-visit interaction as the covariates. An unstructured covariance matrix was used to model the covariance of within-patient scores. The Kenward-Roger approximation \[[@CR21]\] was used to estimate denominator degrees of freedom. The analysis was based on all post-baseline scores using the observed cases (OC) approach without imputation of missing values.

The secondary efficacy parameter, change from baseline in CGI-S score at week 8, was analyzed using an MMRM approach that was similar to the one used for the primary efficacy parameter. To control the overall type I error rate for multiple comparisons across the primary and the secondary efficacy parameters, the matched parallel gatekeeping procedure \[[@CR22]\] was implemented; statistically significant changes from baseline in CGI-S score could therefore only be claimed if differences in the primary outcome were statistically significant in favor of vilazodone. CGI-I score was analyzed using an MMRM approach with the baseline CGI-S score as a covariate. CDRS-R response and remission rates were analyzed using a generalized linear mixed model with random intercept and fixed terms of treatment group, visit, treatment-by-visit interaction, and baseline score. CGI-I response was analyzed post hoc using a last observation carried forward approach. All statistical tests for efficacy analyses were two-sided hypothesis tests performed at the 5% level of significance; confidence intervals (CIs) were two-sided 95% CIs, unless stated otherwise. All safety parameters were analyzed descriptively.

Results {#Sec8}
=======

Patients {#Sec9}
--------

A total of 529 patients were randomized to placebo, vilazodone 15 mg/day, or vilazodone 30 mg/day (Figure [1](#Fig1){ref-type="fig"}). Of the 526 patients in the safety population, 452 (85.9%) completed double-blind treatment (placebo = 83.0%; vilazodone 15 mg = 85.1%; vilazodone 30 mg = 89.4%). The most common reasons for premature discontinuation in the overall study population were withdrawal of consent (4.6%) and AEs (4.0%); discontinuation due to AEs was higher in patients treated with vilazodone (15 mg/day = 5.1%; 30 mg/day = 4.4%) than in patients treated with placebo (2.3%).Fig. 1Patient disposition

Baseline characteristics were similar across treatment groups (Table [1](#Tab1){ref-type="table"}). Mean patient age was approximately 15 years, with a higher percentage of female patients than male patients in each treatment group. Baseline CDRS-R total scores and CGI-S scores indicated similar levels of disease severity across treatment groups, with a CDRS-R total score of ≥ 40 being indicative of depression in adolescents \[[@CR23]\].

Efficacy Outcomes {#Sec10}
-----------------

Mean CDRS-R total scores decreased from baseline to week 8 in all treatment groups, indicating improvement in depressive symptoms; however, the least squares mean difference (LSMD) was not statistically significant for either vilazodone group versus the placebo group (Figure [2](#Fig2){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). After adjustment for multiple comparisons, there was no significant difference between either vilazodone group and placebo in change from baseline to week 8 in CGI-S score (Table [2](#Tab2){ref-type="table"}). There were also no other significant differences in any additional outcome.Fig. 2Change from baseline in CDRS-R total score (ITT Population, MMRM). *CDRS-R* Children's Depression Rating Scale--Revised, *ITT* intent-to-treat, *LS* least squares, *MMRM* mixed-effect model for repeated measures Table 1Demographic and baseline characteristicsDemographic characteristics (safety population)Placebo\
(*n* = 171)Vilazodone\
15 mg/day\
(*n* = 175)Vilazodone\
30 mg/day\
(*n* = 180)Age, mean (SD), years14.9 (1.7)14.9 (1.6)14.6 (1.6)Sex, *n* (%) Male68 (39.8)72 (41.1)73 (40.6) Female103 (60.2)103 (58.9)107 (59.4)Race, *n* (%) White110 (64.3)115 (65.7)121 (67.2) Black or African-American45 (26.3)48 (27.4)49 (27.2) Asian6 (3.5)3 (1.7)0 American Indian or Alaska Native2 (1.2)2 (1.1)4 (2.2) Other8 (4.7)7 (4.0)6 (3.3)Weight, mean (SD), kg71.9 (20.8)70.1 (20.7)70.9 (20.6)Height, mean (SD), cm166.1 (8.9)166.2 (9.3)165.7 (9.1)BMI, mean (SD), kg/m^2^26.0 (7.2)25.3 (6.9)25.7 (6.7)Duration of MDD, mean (SD), years2.4 (2.3)2.6 (2.3)2.4 (2.1)Duration of current episode, mean (SD), months11.0 (12.0)12.0 (14.2)12.6 (14.7)Age at onset, mean (SD), years12.5 (2.5)12.3 (2.7)12.3 (2.6)Baseline efficacy scores (ITT population) CDRS-R total score, mean (SD)57.5 (8.6)57.8 (8.7)56.8 (8.5) CGI-S score, mean (SD)4.5 (0.6)4.6 (0.6)4.6 (0.6)*BMI* body mass index, *CDRS-R* Children's Depression Rating Scale--Revised, *CGI-S* Clinical Global Impressions--Severity, *ITT* intent-to-treat, *MDD* major depressive disorder, *SD* standard deviation Table 2Prespecified and post hoc efficacy outcomes at week 8 (ITT population, MMRM)Placebo\
(*n* = 170)Vilazodone\
15 mg/day\
(*n* = 174)Vilazodone\
30 mg/day\
(*n* = 180)CDRS-R total score Week 8 score (SD)34.0 (12.9)33.8 (12.0)32.5 (11.5) LS mean change from baseline (SE)− 22.5 (0.9)− 22.9 (0.9)− 24.2 (0.9) LSMD vs placebo (95% CI)--− 0.5 (−3.0 to 2.0)− 1.7 (− 4.2 to 0.7) Adjusted *P* value^a^--0.71620.3267 *P* value--0.71620.1634CGI-S total score Week 8 score (SD)2.9 (1.2)2.7 (1.2)2.7 (1.1) LS mean change from baseline (SE)− 1.6 (0.1)− 1.8 (0.1)− 1.9 (0.1) LSMD vs placebo (95% CI)--− 0.2 (− 0.5 to 0.0)− 0.3 (−0.5 to 0.0) Adjusted *P* value^a^--0.71620.3267 *P* value--0.08520.0323CGI-I total score Week 8 score (SD)2.4 (1.1)2.2 (1.2)2.2 (1.0) LS mean score at week 8 (SE)2.4 (0.1)2.3 (0.1)2.2 (0.1) LSMD vs placebo (95% CI)--− 0.1 (− 0.4 to 0.1)− 0.2 (− 0.5 to 0.0) *P* value--0.30720.0563CDRS-R response^b^ Responders, *n* (%)^c^80 (55.9)83 (56.1)103 (63.2) Odds ratio (95% CI)--1.0 (0.5--2.1)1.6 (0.8--3.2)* P* value--0.99070.2115CDRS-R remission^d^ Remitters, *n* (%)^c^63 (44.1)62 (41.9)72 (44.2) Odds ratio (95% CI)--1.0 (0.5--2.0)1.1 (0.5--2.2)* P* value--0.94770.8232CGI-I response, score of 1 or 2 Responders, *n* (%)^e^92 (54.1)98 (56.3)112 (62.2) Odds ratio (95% CI)--1.1 (0.7--1.7)1.4 (0.9--2.1)* P* value--0.68110.1248CGI-I response, score of 1 Responders, *n* (%)^e^34 (20.0)52 (29.9)52 (28.9) Odds ratio (95% CI)--1.7 (1.0--2.8)1.6 (1.0--2.7)* P* value--0.03530.0547*CDRS-R* Children's Depression Rating Scale--Revised, *CGI-I* Clinical Global Impressions--Improvement, *CGI-S* CGI--Severity, *CI* confidence interval, *ITT* intent-to-treat, *LS* least squares, *LSMD* LS mean difference, *MMRM* mixed-effect model for repeated measures, *SD* standard deviation, *SE* standard error^a^Adjusted *P* values were obtained from the matched parallel gatekeeping procedure^b^CDRS-R response defined as ≥ 40% total score improvement from baseline at week 8^c^Analyzed using a generalized linear mixed model; percentages based on the number of patients available for analysis at week 8 in the ITT population (placebo, *n* = 143; vilazodone 15 mg/day, *n* = 148; vilazodone 30 mg/day, *n* = 163)^d^CDRS-R remission defined as total score ≤ 28 at week 8^e^CGI-I response at week 8 was analyzed using a last observation carried forward approach

Safety Outcomes {#Sec11}
---------------

### Extent of Exposure {#Sec12}

The mean (standard deviation) treatment duration was 51.2 (14.0) days for placebo-treated patients and 51.7 (12.3) days and 53.1 (10.6) days for vilazodone 15 mg/day- and 30 mg/day-treated patients, respectively. Median (min, max) treatment duration was 56 (4, 69) days for both placebo- and vilazodone 15 mg/day-treated patients, and 56 (7, 70) for vilazodone 30 mg/day-treated patients. An interim population PK analysis found the 15-mg and 30-mg doses in adolescents achieved exposures similar to 20-mg and 40-mg doses, respectively, in adult patients \[[@CR24]\].

### Adverse Events {#Sec13}

The percentage of patients with one or more treatment-emergent AE (TEAE) was higher in vilazodone-treated patients than in placebo-treated patients (Table [3](#Tab3){ref-type="table"}). TEAEs that occurred in ≥ 5% in either vilazodone treatment group at a rate twice that of placebo were nausea, upper abdominal pain, vomiting, and dizziness. Serious AEs (SAEs) occurred in six patients, including one patient in the placebo group (suicidal ideation), two patients in the vilazodone 15-mg/day group (alanine aminotransferase increased and mental status changes), and three patients in the vilazodone 30-mg/day group (intentional overdose with marketed buspirone and suicide attempt in one patient, pilonidal cyst in one patient, and suicidal ideation in one patient). Each patient with a suicide-related SAE discontinued from the study and recovered. Two patients had suicide-related SAEs that were considered related to treatment \[suicidal ideation (placebo) and intentional overdose/suicide attempt (vilazodone 30 mg/day)\]. TEAEs that led to discontinuation in more than one patient included nausea (vilazodone, *n* = 3; placebo, *n* = 0), nightmares (vilazodone, *n* = 2; placebo, *n* = 0), suicidal ideation (vilazodone, *n* = 4; placebo, *n* = 1), and depression (vilazodone, *n* = 4; placebo, *n* = 0) (Table [4](#Tab4){ref-type="table"}).Table 3Adverse events during the double-blind treatment period (safety population**)**Placebo\
(*n* = 171)\
*n* (%)Vilazodone\
15 mg/day\
(*n* = 175)\
*n* (%)Vilazodone\
30 mg/day\
(*n* = 180)\
*n* (%)Deaths000Any TEAE105 (61.4)122 (69.7)135 (75.0)Any SAE1 (0.6)2 (1.1)3 (1.7)Discontinuations due to AEs4 (2.3)9 (5.1)8 (4.4)Common TEAEs (≥ 2% of patients in both vilazodone groups) Nausea^a^14 (8.2)51 (29.1)49 (27.2) Headache27 (15.8)22 (12.6)29 (16.1) Upper abdominal pain^a^11 (6.4)7 (4.0)28 (15.6) Vomiting^a^6 (3.5)11 (6.3)21 (11.7) Diarrhea8 (4.7)15 (8.6)16 (8.9) Dizziness^a^5 (2.9)8 (4.6)13 (7.2) Nasopharyngitis6 (3.5)6 (3.4)11 (6.1) Abdominal discomfort2 (1.2)7 (4.0)8 (4.4) Upper respiratory tract infection4 (2.3)7 (4.0)7 (3.9) Insomnia5 (2.9)5 (2.9)7 (3.9) Fatigue7 (4.1)4 (2.3)7 (3.9) Decreased appetite1 (0.6)7 (4.0)6 (3.3) Somnolence1 (0.6)8 (4.6)4 (2.2)*AE* adverse event, *SAE* serious AE, *TEAE* treatment-emergent AE^a^Occured in ≥ 5% of patients in either vilazodone group at a rate twice that of placebo Table 4Treatment-emergent adverse events that led to discontinuation (safety population)TEAEPlacebo\
(*n* = 171)\
*n* (%)Vilazodone\
15 mg/day\
(*n* = 175)\
*n* (%)Vilazodone\
30 mg/day\
(*n* = 180)\
*n* (%)Nausea003 (1.7)Nightmare002 (1.1)Suicidal ideation1 (0.6)2 (1.1)2 (1.1)Depression03 (1.7)1 (0.6)Diarrhea001 (0.6)Intentional overdose001 (0.6)Muscle twitching001 (0.6)Suicide attempt001 (0.6)Abdominal discomfort01 (0.6)0Anxiety01 (0.6)0Depressive symptom1 (0.6)00Headache1 (0.6)00Impulsive behavior1 (0.6)00Insomnia01 (0.6)0Irritability01 (0.6)0Mental status change01 (0.6)0*TEAE* treatment-emergent adverse event

### Laboratory Tests, Vital Signs, and Electrocardiograms {#Sec14}

Mean changes from baseline in clinical laboratory parameters and vital signs were generally small and similar among treatment groups. Overall, the incidence of post-baseline potentially clinically significant laboratory values was low and similar in the three treatment groups; no patient met Hy's law criteria \[alanine aminotransferase or aspartate aminotransferase elevation ≥ 3 times the upper limit of normal (ULN), total bilirubin elevation \>2 times ULN, and alkaline phosphatase \<2 times ULN\]. No patient had a QTc of \> 500 ms or a clinically significant ECG; no new safety concerns were identified.

### Suicidal Ideation and Behavior {#Sec15}

There were no completed suicides. Based on C-SSRS findings, the incidences of suicidal ideation (placebo, 33.3%; vilazodone 15 mg/day, 36.0%; vilazodone 30 mg/day, 31.1%) and suicidal behavior (placebo, 1.8%; vilazodone 15 mg/day and 30 mg/day, 1.1%) were similar between treatment groups, although nonspecific active suicidal thoughts were more frequent in the vilazodone 15-mg/day group. Four patients recorded 'yes' to suicide attempt on the C-SSRS (placebo, *n* = 2; vilazodone 15 mg/day and 30 mg/day, *n* = 1 each).

Discussion {#Sec16}
==========

In this randomized, placebo-controlled, double-blind study in adolescent patients with MDD, CDRS-R total score improved from baseline in each treatment group, but the LSMD at week 8 was not statistically significant for either vilazodone 15 mg/day or 30 mg/day versus placebo. Additionally, no significant differences were observed for vilazodone versus placebo in mean change from baseline in CGI-S score when *P* values were adjusted for multiple comparisons. Vilazodone was generally well tolerated, and TEAEs in adolescent patients were similar to what has been observed in adult patients \[[@CR11]--[@CR15]\]. Examining these negative results in the context of other randomized placebo-controlled trials of antidepressants for the treatment of adolescent depression may help explain our findings and expand the base of knowledge pertaining to vilazodone.

Although the optimal treatment for adolescent depression is unclear, clinical guidelines recommend the use of psychosocial interventions, SSRIs, or combined treatment \[[@CR4], [@CR25]\]. However, in clinical trials of antidepressants in pediatric and adolescent patients with MDD, evidence of efficacy is inconsistent, with long-term effectiveness and relapse prevention data lacking in this population \[[@CR5]\]. Several antidepressant agents have encountered difficulties demonstrating a treatment effect versus placebo, with high placebo response rates (up to 60%) contributing to the problem \[[@CR26]\]. Likewise, in our study, improvements in mean change from baseline in CDRS-R total score were large in the placebo group (− 22.5), which may have played a role in our inability to detect treatment differences in either vilazodone group (15 mg/day, − 22.9; 30 mg/day, − 24.2). Moreover, over 50% of patients in the placebo group were rated as very much or much improved (CGI-I response of 1 or 2), supporting a high placebo effect in this treatment group. Additional methodological issues, including study site differences, patient age, inclusion/exclusion criteria, study duration, and outcome measures, have further confounded efficacy outcomes in this therapeutic area \[[@CR27]\].

Despite limitations in the evidence, use of antidepressants in pediatric patients has increased in recent years \[[@CR28]\]. In a meta-analysis of antidepressants in children and adolescents aged 9--18 years, only fluoxetine was found to be significantly more effective than placebo \[[@CR9]\]. Consistent effectiveness data for SSRIs other than fluoxetine is scarce \[[@CR29]--[@CR31]\]; citalopram \[[@CR32]\], escitalopram \[[@CR33]\], sertraline \[[@CR34]\], and paroxetine \[[@CR35]\] have reported potential for benefit in a limited number of clinical trials. Evidence for SNRIs in child and adolescent depression is lacking, with some differences for venlafaxine versus placebo reported in two trials \[[@CR36]\] and two failed trials reported for duloxetine \[[@CR37], [@CR38]\]. Additionally, tricyclic antidepressants have not proven to be more effective than placebo in treating depression in children and adolescents \[[@CR39]\]; they are also associated with more adverse effects than SSRIs or SNRIs and can be fatal in overdose.

Nonpharmacological intervention is considered a first-line treatment for adolescent depression, with 15--30% response reported for brief psychosocial treatment and evidence suggesting that adolescents with moderate depression may benefit from CBT or IPT \[[@CR4], [@CR40]\]. Two meta-analyses have reported efficacy for CBT, with effect sizes on the lower end of moderate (0.34) \[[@CR41], [@CR42]\]. Benefits for IPT have also been reported in randomized clinical trials of adolescents with depression \[[@CR43], [@CR44]\], including in one study conducted in a school setting \[[@CR45]\]. Studies evaluating combined pharmacotherapy and CBT have mixed results, and further research is warranted to evaluate under what circumstances adding nonpharmacological therapy to pharmacological treatment is beneficial \[[@CR31], [@CR46], [@CR47]\].

Although the safety and tolerability of pharmacological treatment are always a primary concern, lack of clear efficacy evidence for some antidepressants in adolescent patients creates an even greater imperative to assess benefits versus harms. Although adverse effects are commonly reported in both active- and placebo-treated patients in adolescent antidepressant studies, reported events are generally similar to those reported in adult trials, and few AEs occur more frequently in children and adolescents than in adults \[[@CR27]\]. In our vilazodone study, gastrointestinal events and headache were the most commonly reported TEAEs in vilazodone- and placebo-treated patients. Rates of discontinuation due to AEs, which is a good measure of general tolerability, were relatively low in patients treated with vilazodone (15 mg/day = 5.1%; 30 mg/day = 4.4%), although they were higher than in placebo-treated patients (2.3%).

The most troubling safety issue concerning adolescent patients with depression is the reported link between suicidality and antidepressants in young patients \[[@CR48], [@CR49]\]. Since any prospect of potential suicidality is a grave concern, the risk of harm and the potential benefits of treatment must be carefully factored into an informed decision regarding how to treat adolescents with antidepressants \[[@CR27]\]. Of note in our study, results of the C-SSRS indicate incidences of suicidal ideation and behavior were similar overall among each treatment group.

Limitations of our study include the lack of an active control, the short duration of treatment, and strict inclusion and exclusion criteria that may limit the generalizability of the results. High placebo response may have limited the ability to detect a statistical difference between the vilazodone- and placebo-treatment groups; however, the mean decrease in CDRS-R scores suggests that individual treatment effect likely occurred for some patients. Additional methodological factors (e.g., number of study sites, inclusion/exclusion criteria, study site differences) may have further affected the results of our study.

Conclusions {#Sec17}
===========

In this double-blind randomized clinical trial of adolescents with MDD, no significant differences between vilazodone and placebo were observed on the primary efficacy parameter; high placebo response may have contributed to an inability to detect a treatment effect. Vilazodone was generally safe and well tolerated, with adverse effects similar to what has been observed in trials of adult patients \[[@CR11]--[@CR14]\]. Clinical trial evidence for pharmacological treatment options in moderate to severe adolescent depression is not robust, with only a few agents (i.e., fluoxetine and escitalopram) reporting positive results \[[@CR6]--[@CR8]\]. Effective treatment options for adolescents with depression are an unmet medical need.
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